October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE Read more
August 22, 2023 Non Regulatory ”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW Read more
April 26, 2023 Non Regulatory Welcome to an InDex Pharmaceuticals business update presentation in Stockholm on May 9, from 13:00 to 15.30 CET Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod Read more